Small-cap biotech stocks like Intellia and Vir are seen as potential triple winners despite market hurdles.

Small-cap stocks under $10, including Intellia Therapeutics, Vir Biotechnology, and others, are highlighted for their potential to triple in value despite market challenges. These companies, focusing on innovative treatments for diseases, are backed by hedge funds and benefit from factors like mergers and acquisitions recovery, stabilizing inflation, and technological advancements. Despite facing issues like trade tensions and higher interest rates, small-cap stocks are expected to outperform large-cap stocks in 2025.